Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | METAP2 | P50579 | 5/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.33 |
| ▸ | METAP1 | P53582 | 2/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | F12 | P00748 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | F7 | P08709 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927275 | 0.90 | METAP2 (0.36) | F2METAP2EPHX1METAP1 | |
| SCHEMBL6926519 | 0.89 | METAP2 (0.35) | F2METAP2EPHX1METAP1 | |
| SCHEMBL6926522 | 0.84 | F2 (0.47) | F2METAP2EPHX1METAP1F10 | |
| SCHEMBL6924571 | 0.81 | TP53 (0.34) | F2METAP2 | |
| SCHEMBL6921549 | 0.80 | METAP2 (0.34) | F2METAP2EPHX1METAP1 | |
| SCHEMBL6925791 | 0.79 | F2 (0.40) | F2METAP2METAP1F10F12 | |
| SCHEMBL6927350 | 0.77 | F2 (0.41) | F2METAP2EPHX1METAP1F10 | |
| SCHEMBL7594538 | 0.75 | METAP2 (0.35) | F2METAP2EPHX1METAP1 | |
| SCHEMBL6924396 | 0.73 | CXCR3 (0.36) | F2METAP2EPHX1METAP1 | |
| SCHEMBL6077123 | 0.71 | EPHX1 (0.35) | METAP2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | F2 2/4885METAP2 1075/4885EPHX1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.